case
middl
east
respiratori
syndrom
coronaviru
merscov
continu
occur
make
one
target
acceler
vaccin
develop
one
vaccin
candid
base
liveattenu
measl
viru
mv
vaccin
encod
merscov
spike
glycoprotein
merss
mv
merss
h
induc
robust
humor
cellular
immun
merss
mediat
protect
induct
natur
immun
vaccin
mv
merss
h
novel
mv
mersn
character
focus
necess
vector
replic
natur
induc
cell
sinc
function
cell
contribut
importantli
clearanc
merscov
immun
merscov
mv
detect
mvsuscept
mice
immun
uvinactiv
viru
replicationcompet
mv
merss
h
trigger
robust
neutral
antibodi
titer
also
adult
mice
furthermor
signific
fraction
mer
covspecif
cell
mvspecif
cell
simultan
express
induc
reveal
mv
merss
h
induc
multifunct
cellular
immun
middl
east
respiratori
syndrom
coronaviru
merscov
member
coronavirida
famili
emerg
kingdom
saudi
arabia
zaki
et
al
coronavirus
typic
caus
mild
infect
upper
respiratori
tract
alreadi
sever
acut
respiratori
syndrom
cov
sarscov
mortal
rate
among
infect
patient
introduc
human
popul
sarscov
spread
worldwid
caus
diagnos
infect
contain
within
year
emerg
http
en
contrast
infect
merscov
ongo
year
laboratoryconfirm
case
distribut
countri
least
death
report
novemb
http
wwwwhointemergenciesmerscoven
appar
casefat
rate
grave
concern
epidem
spread
observ
sarscov
could
result
disastr
death
toll
merscov
introduc
zoonot
transmiss
dromedari
camel
human
patient
alagaili
et
al
haagman
et
al
reusken
et
al
serolog
studi
indic
widespread
earli
distribut
among
anim
host
alagaili
et
al
reusken
et
al
therefor
continu
risk
transmiss
especi
person
close
contact
camel
evid
fortun
human
human
transmiss
rate
remain
low
asid
individu
regular
contact
camel
health
care
worker
rel
merscov
patient
consider
risk
infect
alraddadi
et
al
drosten
et
al
still
modest
level
nonetheless
high
case
fatal
rate
recurr
outbreak
merscov
infect
especi
risk
viru
adapt
potenti
result
epidem
even
pandem
spread
make
develop
effect
vaccin
merscov
intern
prioriti
efficaci
sever
vaccin
candid
demonstr
differ
anim
model
even
dromedari
camel
review
okba
et
al
one
candid
mv
merss
h
malczyk
et
al
base
measl
viru
mv
vaccin
platform
technolog
encod
merscov
spike
protein
addit
antigen
backbon
recombin
mv
del
vall
et
al
resembl
vaccin
strain
moraten
author
use
us
sinc
candid
induc
robust
humor
function
cellular
immunerespons
merscov
moreov
merscov
viral
load
inflamm
lung
significantli
reduc
challeng
mice
vaccin
mv
merss
h
malczyk
et
al
experi
provid
proof
concept
efficaci
vaccin
candid
mechanist
insight
natur
induc
cell
respons
remain
elucid
special
interest
sinc
shown
cell
essenti
clearanc
infect
coleman
et
al
zhao
et
al
deplet
cell
increas
overal
inflamm
bronchiolar
inflamm
lymphocyt
infiltr
pleuriti
day
postinfect
mice
coleman
et
al
mer
covsuscept
mice
deplet
cell
unabl
clear
viru
altern
spike
glycoprotein
conserv
intern
structur
protein
nucleocapsid
protein
n
special
interest
put
target
antivir
cell
respons
trigger
futur
mer
vaccin
therefor
also
gener
character
merscov
n
proteinencod
vaccin
candid
base
mv
vaccin
platform
studi
character
induct
mer
covspecif
immun
respons
first
analyz
necess
viral
replic
induct
mer
covand
mvspecif
immun
respons
use
highli
immunogen
mv
merss
h
vaccin
candid
addit
character
function
cell
respons
juvenil
week
old
adult
month
age
mice
use
flow
cytometri
function
assay
vero
african
green
monkey
kidney
atcc
atcc
cell
line
purchas
atcc
manassa
va
usa
cultur
dulbecco
modifi
eagl
medium
dmem
biowest
franc
supplement
fetal
bovin
serum
fb
biochrom
berlin
germani
mm
lglutamin
lgln
biochrom
jawsii
dendrit
cell
atcc
purchas
atcc
cultur
ribonucleosid
deoxyribonucleosid
gibco
brl
eggenstein
germani
supplement
fb
mm
lgln
mm
sodium
pyruv
biochrom
ngml
murin
gmcsf
peprotech
hamburg
germani
murin
dendrit
cell
shen
et
al
cultur
rpmi
contain
fb
mm
lgln
nonessenti
aminoacid
biochrom
mm
hepe
ph
sigmaaldrich
steinheim
germani
cell
cultur
humidifi
atmospher
contain
co
maximum
month
cultur
thaw
origin
stock
codonoptim
gene
encod
merscovn
genebank
access
flank
aatiimlui
bind
site
plasmid
pmarqmersn
obtain
gene
synthesi
invitrogen
life
technolog
regensburg
germani
antigen
immedi
earli
cytomegaloviru
cmv
promot
martin
et
al
insert
plasmid
p
brmv
atu
p
del
vall
et
al
p
mv
gfp
h
via
mluiaatii
sfiisacii
respect
gener
p
poliimv
mersn
p
p
poliimv
mersn
h
construct
lentivir
transfervector
encod
merscovn
orf
mersn
amplifi
pcr
primer
encompass
flank
restrict
site
nheixhoi
templat
pmarqmersn
detail
primer
pcr
avail
upon
request
pcr
product
clone
invitrogen
life
technolog
fulli
sequenc
intact
antigen
orf
clone
hewett
et
al
use
nheixhoi
restrict
site
yield
lentivir
vector
produc
use
gener
antigenexpress
dendrit
cell
line
describ
malczyk
et
al
short
vector
gener
use
standard
plasmid
system
transfer
vector
plasmid
pei
transfect
subsequ
purif
harvest
transfect
cell
yield
viru
stock
use
transduc
dc
cell
line
singl
cellsort
fac
select
antigen
express
mersn
encod
vaccin
candid
mv
mersn
p
mv
mersn
h
rescu
describ
malczyk
et
al
martin
et
al
singl
syncytia
pick
overlaid
onto
confluent
vero
cell
cultur
plate
harvest
passag
scrape
freezethaw
cycl
cell
time
maxim
infect
subsequ
passag
gener
describ
follow
virus
mersn
encod
vaccin
virus
use
character
virus
vaccin
merss
encod
vaccin
viru
mv
merss
h
control
viru
mv
atu
p
malczyk
et
al
also
use
vaccin
well
mv
gfp
p
merscov
isol
zaki
et
al
use
neutral
assay
propag
titrat
vero
cell
method
spearman
kaerber
hubert
mv
merss
h
inactiv
uvirradi
use
uv
crosslink
uvp
cambridg
uk
viru
suspens
ice
expos
uv
light
nm
cm
distanc
uv
sourc
min
inactiv
viru
control
incub
vero
cell
control
aliquot
inactiv
parallel
viru
stock
store
aliquot
cell
lyse
immunoblot
previous
describ
funk
et
al
rabbit
antimerscov
serum
use
primari
antibodi
merscovn
rabbit
antimvn
polyclon
antibodi
abcam
mvn
detect
donkey
hrpcoupl
antirabbit
igg
h
l
polyclon
antibodi
rockland
gilbertsvil
pa
serv
secondari
antibodi
peroxidas
activ
visual
enhanc
chemiluminesc
detect
kit
thermo
scientif
bremen
germani
amersham
hyperfilm
ecl
ge
healthcar
freiburg
germani
anim
experi
carri
complianc
regul
german
anim
protect
law
author
rp
darmstadt
sixto
month
old
ifnar
mice
mrkic
et
al
defici
type
ifn
receptor
transgen
express
human
inocul
intraperiton
ip
tcid
recombin
virus
uvinactiv
vaccin
prepar
day
either
day
mice
bled
day
post
initi
infect
pi
serum
sampl
store
mice
euthan
day
pi
splenocyt
harvest
assess
cellular
immun
respons
quantif
vnt
done
describ
malczyk
et
al
brief
mous
sera
serial
dilut
dilut
step
dmem
duplic
total
pfu
mv
gfp
p
tcid
merscov
strain
mix
dilut
sera
incub
h
viru
suspens
ad
vero
cell
seed
h
prior
assay
plate
incub
day
vnt
calcul
reciproc
highest
mean
dilut
abolish
infect
murin
gamma
interferon
enzymelink
immunosorb
spot
elispot
assay
ebiosci
frankfurt
germani
perform
accord
manufactur
instruct
use
multiscreen
immunoprecipit
ip
elispot
polyvinyliden
difluorid
pvdf
plate
merck
millipor
darmstadt
germani
isol
medium
inocul
mice
serv
mock
control
vnt
calcul
highest
dilut
abolish
infect
dot
repres
singl
anim
n
horizont
line
repres
mean
per
group
yaxi
start
detect
limit
mice
detect
limit
detect
vnt
g
secret
antigenspecif
restimul
splenocyt
harvest
day
post
prime
immun
cocultur
jawsii
left
middl
dendrit
cell
transgen
mersn
black
untransduc
control
nc
white
right
analyz
cellular
respons
direct
mv
splenocyt
stimul
mv
bulk
antigen
mv
bulk
left
unstimul
sham
reactiv
splenocyt
confirm
cona
treatment
tcid
tissu
cultur
infecti
dose
onewayanova
tukey
multipl
comparison
p
p
p
p
splenocyt
cocultur
differ
stimuli
rpmi
fb
mm
lgln
penicillinstreptomycin
h
restimul
mer
nspecif
cell
splenocyt
cocultiv
jawsii
dendrit
cell
clone
either
cell
line
encod
mersn
hand
splenocyt
stimul
mv
bulk
antigen
serion
immunolog
germani
mer
sderiv
peptid
biosynthesi
inc
lewisvil
tx
usa
channappanavar
et
al
siinfekl
control
peptid
sin
ovalbumin
aa
invivogen
san
diego
ca
usa
appropri
gener
cell
stimul
concanavalin
cona
sigmaaldrich
st
loui
mo
usa
use
neg
control
splenocyt
left
untreat
h
cell
remov
plate
plate
incub
biotinconjug
antibodi
avidinhrp
accord
manufactur
instruct
aec
sigmaaldrich
substrat
solut
develop
spot
prepar
accord
manufactur
instruct
use
aec
dissolv
n
ndimethylformamid
merck
millipor
use
peroxidasedepend
stain
afterward
spot
count
use
eliscan
elispot
scanner
aelvi
hamburg
germani
elispot
analysi
softwar
elianalys
aelvi
flow
cytometrybas
determin
cytokin
express
intracellular
cytokin
stain
ic
splenocyt
vaccin
mice
isol
splenocyt
per
mous
cultiv
fb
mm
lgln
nonessenti
amino
acid
biochrom
mm
hepe
penicillinstreptomycin
brefeldin
sigmaaldrich
one
stimuli
also
use
elispot
analysi
gener
cell
stimul
tetradecanoylphorbol
acet
tpa
sigma
aldrich
ionomycin
iono
sigmaaldrich
use
posit
control
medium
use
neg
control
splenocyt
stimul
h
subsequ
cell
stain
fixabl
viabil
dye
ebiosci
bd
franklin
lake
nj
usa
bd
permeabil
fixationpermeabil
solut
bd
perm
wash
buffer
bd
stain
bd
bd
cell
fix
icecold
paraformaldehyd
pfa
pb
analyz
via
flow
cytometri
use
lsrii
sorp
flow
cytomet
bd
fc
express
softwar
de
novo
softwar
glendal
ca
usa
sinc
nucleocapsid
protein
n
cov
quit
conserv
regard
appropri
target
induc
antivir
cell
therefor
merscov
n
chosen
altern
antigen
express
recombin
mv
vaccin
platform
fulllength
mersn
clone
two
differ
addit
transcript
unit
atu
either
behind
p
post
p
h
post
h
cassett
measl
vaccin
strain
mv
genom
viru
clone
success
rescu
amplifi
vero
cell
titer
tcid
ml
essenti
verif
antigen
express
western
blot
analysi
vero
cell
infect
mv
mersn
vaccin
reveal
express
n
antigen
littl
impact
genom
posit
transgen
cassett
fig
growth
kinet
show
impair
viru
replic
compar
respect
mv
gfp
p
control
viru
fig
b
c
test
efficaci
mv
mersn
candid
vivo
genet
modifi
ifnar
mice
chosen
sinc
prime
small
anim
model
analysi
mvderiv
vaccin
mrkic
et
al
thu
mice
per
group
inocul
via
intraperiton
ip
rout
day
time
tcid
mv
mersn
p
mv
mersn
h
empti
control
viru
mv
atu
p
mediuminocul
mice
serv
neg
control
day
four
day
boost
immun
sera
splenocyt
immun
mice
sampl
respect
fig
expect
mice
immun
recombin
mv
includ
control
viru
develop
high
mv
viru
neutral
titer
vnt
vnt
fig
littl
evid
induct
neutral
antibodi
merscov
found
mice
expect
intraparticular
antigen
fig
vnt
mv
merscov
detect
control
mice
inocul
medium
alon
analyz
splenocyt
anim
vaccin
mv
mersn
h
control
anim
inocul
medium
mv
atu
p
elispot
assay
antigenspecif
secret
antigenspecif
cell
restimul
vitro
syngen
murin
dc
cell
line
jawsii
genet
modifi
lentivir
vector
transduct
stabli
express
mersn
protein
therebi
present
respect
cell
epitop
mhc
singl
cell
clone
deriv
flow
cytometr
sort
singl
gfpposit
cell
antigen
express
transduc
dc
verifi
western
blot
analysi
data
shown
elispot
assay
use
splenocyt
vaccin
anim
cocultur
jawsiimersn
reveal
secret
cell
per
splenocyt
immun
mv
mersn
h
fig
signific
control
addit
cellular
immun
respons
target
mv
antigen
detect
upon
stimul
mv
bulk
antigen
vaccin
mice
receiv
recombin
viru
expect
howev
mv
bulk
antigen
stimul
secret
cell
per
splenocyt
mv
vaccin
anim
describ
malczyk
et
al
final
splenocyt
mice
reveal
similar
basic
reactiv
unspecif
cell
stimul
confirm
similar
number
secret
cell
upon
cona
treatment
fig
thu
gener
mvbase
vaccin
platform
express
mersn
induc
signific
mer
nspecif
cellular
immun
respons
desir
case
humor
cellular
respons
induc
vaccin
candid
mv
merss
consider
higher
previou
analys
similar
condit
malczyk
et
al
therefor
character
antimerscov
immun
induc
mv
deriv
vaccin
proceed
merss
encod
vaccin
candid
yield
approxim
higher
number
reactiv
cell
vaccin
sinc
mer
vaccin
candid
mv
merss
h
induc
robust
protect
humor
cellular
immun
respons
ifnar
mice
malczyk
et
al
interest
necess
viral
replic
lifeattenu
vaccin
induct
mer
covspecif
immun
analys
ifnar
mice
chosen
anim
model
sinc
mice
standard
anim
model
analysi
mvderiv
vaccin
genet
composit
compat
establish
merscov
challeng
model
shown
malczyk
et
al
size
allow
hous
regularli
avail
condit
oppos
dromedari
camel
know
natur
host
merscov
date
morbillivirus
mvbase
vaccin
virion
highli
cellassoci
transfer
antigen
protein
within
vaccin
prepar
exclud
therefor
vaccin
mvsuscept
mice
either
tcid
live
formul
quantiti
uvinactiv
mv
merss
h
primeboost
regimen
fig
mv
atu
p
encod
addit
antigen
includ
vector
control
blood
drawn
mice
day
vaccin
day
postimmun
serum
sampl
test
abil
neutral
mv
gfp
p
fig
f
merscov
fig
e
g
sera
mice
neutral
antibodi
either
viru
fig
c
first
immun
live
viru
prepar
induc
neutral
antibodi
mv
mv
atu
p
trigger
significantli
higher
titer
vnt
mv
merss
h
vnt
second
immun
antimv
vnt
increas
titer
cohort
contrast
one
four
anim
uvinactiv
vaccin
group
borderlin
neutral
antibodi
titer
first
immun
anoth
anim
titer
boost
mv
atu
p
uvinactiv
mv
merss
h
vaccin
induc
neutral
antibodi
merscov
background
level
cours
experi
group
vaccin
live
mv
merss
h
develop
titer
around
first
immun
mean
boost
taken
togeth
data
reveal
replic
vaccin
necessari
induc
function
antibodi
respons
mv
addit
antigen
merss
assess
capac
differ
mv
merss
h
vaccin
prepar
induc
merscov
sspecif
cellular
immun
respons
splenocyt
mice
alreadi
test
humor
respons
fig
isol
analyz
day
immun
antigen
ag
depend
secret
use
elispot
assay
isol
splenocyt
restimul
merss
immunodomin
peptid
channappanavar
et
al
mv
bulk
antigen
mv
bulk
analyz
mvspecif
cellular
immun
respons
ovalbuminderiv
siinfeklpeptid
sin
serv
peptid
neg
control
cell
left
untreat
mock
stimul
concanavalin
cona
use
confirm
gener
cell
reactiv
splenocyt
prepar
fig
splenocyt
mice
respond
cona
spot
per
splenocyt
anim
vaccin
live
mv
merss
h
could
stimul
mer
sspecif
peptid
reach
mean
valu
spot
per
splenocyt
contrast
splenocyt
uvinactiv
group
control
viru
mv
atu
p
could
restimul
secret
furthermor
replicationcompet
vaccin
virus
induc
mvspecif
cellular
immun
respons
vaccin
mice
restimul
mv
bulk
ag
induc
mean
spot
per
splenocyt
mv
merss
h
mv
atu
p
vaccin
mice
respect
consequ
replic
vaccin
candid
essenti
induc
arm
immun
system
respons
mv
well
addit
merss
antigen
usual
week
old
juvenil
mice
use
merscov
neutral
antibodi
sera
b
c
mice
sera
mice
e
primeor
f
g
boostimmun
oneway
anova
tukey
multipl
comparison
p
p
p
p
h
secret
antigenspecif
restimul
splenocyt
elispot
analysi
use
splenocyt
mice
vaccin
day
indic
vaccin
isol
day
boost
immun
incub
indic
stimuli
merss
peptid
mv
bulk
antigen
mv
bulk
immunodomin
ovalbuminderiv
siinfeklpeptid
sin
peptid
neg
control
untreat
mock
reactiv
splenocyt
confirm
concanavalin
cona
treatment
number
cell
per
splenocyt
repres
amount
cell
express
upon
restimul
dot
repres
individu
anim
horizont
bar
mean
oneway
anova
tukey
multipl
comparison
p
bs
bodmer
et
al
virolog
immun
studi
evalu
agedepend
chang
vaccin
efficaci
approxim
monthsold
mice
vaccin
mv
merss
h
primeboost
vaccin
scheme
week
prime
boost
vaccin
fig
mice
sacrif
day
postimmun
splenocyt
restimul
mvantigen
merss
peptid
found
reactiv
cell
also
specif
induc
mice
age
fig
mean
spot
per
splenocyt
detect
upon
restimul
mv
bulk
antigen
wherea
spot
per
splenocyt
induc
restimul
mer
sderiv
peptid
illustr
mvand
merscovspecif
cellular
immun
respons
effect
induc
adult
mice
gain
detail
insight
qualiti
observ
cell
respons
character
respons
cell
popul
flow
cytometri
determin
express
surfac
marker
well
upon
restimul
mv
bulk
antigen
posit
stimulu
cell
activ
tetradecanoylphorbolacet
ionomycin
tpaiono
use
exocytosi
cytokin
block
addit
brefeldin
ml
stimul
cell
permeabil
label
fix
flow
cytometri
gate
strategi
exclud
duplic
shown
select
live
cell
fig
upper
panel
separ
cell
fig
lower
panel
select
cell
analyz
express
fig
left
panel
fig
middl
panel
fig
right
panel
exemplarili
shown
splenocyt
restimul
merss
peptid
likewis
cell
express
fig
left
panel
fig
middl
panel
fig
right
panel
depict
restimul
mv
bulk
antigen
vaccin
mv
merss
h
induc
signific
amount
mer
sspecif
cell
express
either
fig
left
panel
fig
middl
panel
mean
total
posit
cell
respect
among
signific
fraction
cell
reveal
multifunct
mean
cell
respons
cell
posit
cytokin
fig
right
panel
moreov
vaccin
induc
signific
fraction
vectorspecif
cell
express
fig
left
panel
fig
middl
panel
upon
restimul
mv
bulk
antigen
among
multifunct
cell
express
cytokin
induc
mean
fig
right
panel
conclud
vaccin
mv
merss
h
induc
express
cell
direct
merscov
mv
also
signific
fraction
multifunct
cytotox
cell
specif
merss
cell
specif
mv
antigen
illustr
broad
robust
merscovspecif
immun
respons
induc
vaccin
mv
merss
h
studi
aim
understand
induct
immun
function
induc
cell
respons
vaccin
mv
merss
h
vaccin
candid
induc
protect
immun
merscov
appropri
anim
model
parallel
gener
test
also
altern
mvbase
vaccin
candid
express
merscov
n
protein
conserv
cell
antigen
mv
mersn
vaccin
candid
inde
induc
signific
antigenspecif
cellular
immun
respons
vaccin
transgen
mice
reveal
also
mer
nexpress
recombin
mv
may
use
role
combat
merscov
sinc
immun
respons
induc
merss
express
candid
nevertheless
consider
higher
proceed
sexpress
vaccin
viru
character
induct
antimerscov
immun
mvbase
vector
use
mv
merss
h
robust
antim
cov
immun
respons
induc
also
older
mice
replic
vaccin
vector
necessari
induc
either
arm
adapt
immun
vector
pathogen
furthermor
vaccin
mv
merss
h
trigger
signific
number
multifunct
mer
sspecif
cell
mvspecif
cell
simultan
produc
upon
stimul
respect
antigen
sinc
number
also
qualiti
induc
mer
covspecif
cell
respons
might
relev
protect
merscov
quit
encourag
see
approx
reactiv
cell
also
express
wherea
revers
cell
coexpress
upon
stimul
immunedomin
merss
peptid
induct
multifunct
cell
quit
accord
previou
studi
sinc
potenti
mv
natur
infect
recombin
mv
induc
multifunct
antigenspecif
cell
alreadi
demonstr
infect
macaqu
wildtyp
mv
induc
polyfunct
cell
specif
mv
protein
increas
number
cell
secret
well
time
nelson
et
al
polyfunct
cell
direct
mvh
expand
pbmc
human
donor
ndhlovu
et
al
likewis
hivvaccin
candid
encod
gag
rt
nef
clade
b
clade
c
strain
foreign
antigen
induc
antigenspecif
multifunct
cell
simultan
express
mice
also
macaqu
steb
et
al
steb
et
al
combin
indic
function
cell
fig
restimul
subject
intracellular
stain
ic
stain
extracellular
tcell
marker
flow
cytometri
analysi
c
gate
strategi
analysi
tcell
express
within
splenocyt
stimul
b
peptid
c
mvbulk
ag
duplic
shown
dead
cell
exclud
analysi
b
c
cell
separ
subject
analysi
left
panel
middl
panel
doubleposit
cell
right
panel
quantif
flow
cytometri
data
e
posit
cell
incub
indic
stimuli
mer
sspecif
peptid
mv
bulk
ag
mv
bulk
immunodomin
ovalbuminderiv
siinfeklpeptid
sin
peptid
neg
control
untreat
cell
mock
reactiv
splenocyt
confirm
tetradecanoylphorbolacet
ionomycin
tpaiono
treatment
dot
repres
individu
anim
horizont
bar
mean
repeatedmeasur
oneway
anova
tukey
multipl
comparison
p
higher
potenc
gener
express
sign
induct
memori
cell
william
et
al
studi
strong
correl
express
thu
indic
high
function
induc
cell
respons
extens
antibodi
panel
detect
could
yield
insight
durabl
cell
respons
induc
mv
vaccin
platform
futur
studi
multifunct
cell
specif
merscov
may
becom
especi
import
sinc
mous
studi
shown
cell
crucial
clearanc
merscov
infect
coleman
et
al
zhao
et
al
noteworthi
viral
infect
human
immunodefici
viru
hiv
modifi
vaccinia
viru
ankara
mva
cytomegaloviru
cmv
amount
produc
cell
correl
ctl
kill
effect
multifunction
antigenspecif
cell
invers
correl
viral
load
bett
et
al
lichterfeld
et
al
precopio
et
al
sandberg
et
al
underlin
import
multifunction
besid
cellular
immun
respons
also
consider
humor
immun
induc
vaccin
anim
mean
vnt
somewhat
lower
expect
malczyk
et
al
still
quit
high
altern
vaccin
candid
deriv
modifi
vaccinia
viru
ankara
mvamerss
reveal
protect
dromedari
camel
natur
host
merscov
haagman
et
al
passiv
immunotherapi
dromedari
immun
sera
significantli
reduc
merscov
titer
lung
tissu
challeng
mice
start
vnt
zhao
et
al
neutral
antibodi
titer
reconvalesc
plasma
human
patient
diagnos
mer
determin
microneutr
test
two
previou
studi
averag
arabi
et
al
zhao
et
al
furthermor
prnt
titer
least
requir
lower
viru
titer
log
mice
challeng
transfer
human
reconvalesc
plasma
zhao
et
al
titer
exceed
studi
addit
mv
merss
h
induc
higher
antimerss
titer
mice
mvamerss
balbc
mice
compar
studi
use
similar
viru
titer
vaccin
malczyk
et
al
volz
et
al
thu
indic
least
compar
efficaci
thu
also
vnt
determin
indic
efficaci
anyway
statist
differ
publish
mv
merss
h
malczyk
et
al
nevertheless
exact
correl
protect
merscov
remain
determin
futur
studi
sinc
essenti
evalu
efficaci
differ
vaccin
candid
import
benchmark
contrast
uvinactiv
mv
merss
h
induc
antibodi
abl
neutral
merscov
mv
neutral
antibodi
principl
also
induc
inactiv
vaccin
protein
eg
fulllength
truncat
merss
protein
combin
adjuv
wang
et
al
obvious
amount
merss
antigen
within
mv
merss
h
vaccin
formul
adjuv
effect
inactiv
suffici
applic
therefor
replic
mvderiv
mer
vaccin
candid
necessari
induct
immun
respons
vector
antigen
interest
vaccin
anim
inde
induct
cellular
immun
usual
effici
de
novo
express
antigen
immun
consequ
applic
replic
compet
vaccin
platform
justifi
robustli
induc
potent
respons
arm
adapt
immun
system
power
immun
respons
induc
juvenil
mice
week
age
also
adult
mice
older
half
year
age
quit
interest
sinc
adult
vaccine
also
target
group
vaccin
respons
merscov
outbreak
defin
target
product
profil
http
wwwwhoint
blueprintwhatresearchdevelopmentmerscovtpp
remark
mv
vaccin
strain
viru
encod
chikungunya
viru
chikv
antigen
alreadi
test
phase
clinic
trial
adult
human
vaccine
year
old
ramsauer
et
al
adult
test
subject
develop
signific
humor
immun
chikv
despit
adult
age
interestingli
also
independ
measl
preimmun
taken
togeth
studi
show
mv
merss
h
induc
surprisingli
high
number
multifunct
cell
specif
merss
also
adult
test
subject
result
replic
recombin
vector
therefor
high
qualiti
cellular
immun
respons
induc
addit
robust
antibodi
respons
vaccin
candid
qualifi
mv
merss
h
evalu
vaccin
candid
merscov
parallel
mersn
encod
mv
option
gener
protect
mer
futur
studi
construct
